Fundraising FoxImmunocodex
Boston, US · 1 known investors
Find your way into Immunocodex
Sign up to find every way you can get introduced to Immunocodex
- Your email: who you already know at Immunocodex, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Immunocodex team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Immunocodex develops lipid nanoparticle mRNA-based therapies targeting dendritic cells to induce immune tolerance for the treatment of autoimmune diseases. The company employs a precision approach that aims to re-program immune cells to suppress inflammatory responses while avoiding broad immunosuppression.
Founders & leadership
MC
Mark CarthyFounder and CEO
FJ
Francisco J. QuintanaScientific Founder
Investors · 1
Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M
How we know: Pfizer Venture Investments's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Immunocodex do?
- Immunocodex develops lipid nanoparticle mRNA-based therapies targeting dendritic cells to induce immune tolerance for the treatment of autoimmune diseases. The company employs a precision approach that aims to re-program immune cells to suppress inflammatory responses while avoiding broad immunosuppression.
- Who founded Immunocodex?
- Immunocodex was founded by Mark Carthy, Francisco J. Quintana.
- Who are Immunocodex's investors?
- Immunocodex's investors include Pfizer Venture Investments.
- Where is Immunocodex headquartered?
- Immunocodex is headquartered in Boston, US.